Company intelligence / Profile preview

MDLifespan

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

MDLifespan's PlasmaXchange™ protocols, including MDL Mold PlasmaXchange™, achieve rapid and substantial reductions in environmental and metabolic toxins based on a published peer-reviewed study and real-world patient outcomes. Clinical data indicate 99% phthalate reduction, 85% lead reduction, 75% glyphosate reduction, and 95% inflammatory marker reduction in healthy adults, with a 90% reduction in mold toxins compared to 17–30% for conventional approaches.

Therapeutic areas: CardiovascularImmunologyWomen's HealthNeurologyOtherOncology
Modalities: DeviceTherapeutic Plasma ExchangeRegenerative therapy
Industry: Non-Academic Healthcare

Partnerships

Collaboration with Dr. Jill Carnahan (mold illness expert)

Beyond the preview

Go deeper on MDLifespan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDLifespan.

Explore the full profile